Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 802-812

  Zembruski, Nadine Cécile Luise ^a   Büchel, Gabriele ^a   Jödicke, Lisa ^a   Herzog, Melanie ^a   Haefeli, Walter Emil ^a   Weiss, Johanna ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Drug interactions; Elvitegravir; Maraviroc; Raltegravir; Vicriviroc

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CALCEIN; ELVITEGRAVIR; GLYCOPROTEIN P; MARAVIROC; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PHEOPHORBIDE; PREGNANE X RECEPTOR; RALTEGRAVIR; VICRIVIROC;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-RETROVIRAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CELL SURVIVAL; CYCLOHEXANES; DOGS; GENE EXPRESSION PROFILING; PIPERAZINES; PYRIMIDINES; PYRROLIDINONES; QUINOLONES; TRIAZOLES;

EID: 79952796060     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq501     Document Type: Article

References (61)

1. Gazzard BG, Anderson J, Babiker A et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
2. Este JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res 2010; 85: 25-33.
3. Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 2008; 57: 1-10.
4. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2010; 85: 176-89.
5. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344: 984-96.
6. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237-42.
7. Huisman MT, Smit JW, Crommentuyn KM et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16: 2295-301.
8. Jones K, Bray PG, Khoo SH et al. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001; 15: 1353-8.
9. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802.
10. Dixit V, Hariparsad N, Li F et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35: 1853-9.
11. Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2009; 48: 211-41.
12. Walker DK, Abel S, Comby P et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005; 33: 587-95.
13. Walker DK, Bowers SJ, Mitchell RJ et al. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008; 38: 1330-9.
14. Ramanathan S, Abel S, Tweedy S et al. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr 2010; 53: 209-14.
15. Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 2009; 14: 607-18.
16. Abel S, Jenkins TM, Whitlock LA et al. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1: 38-46.
17. Summary of Product Characteristics ISENTRESS 400 mg film-coated tablets. Published 12/05/2010. http://www.ema.europa.eu/humandocs/Humans/EPAR/isentress/isentress.htm (22 June 2010, date last accessed).
18. Tricot L, Teicher E, Peytavin G et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-52.
19. Ghosal A, Ramanathan R, Yuan Y et al. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos 2007; 35: 2186-95.
20. Evers R, Cnubben NH, Wijnholds J et al. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett 1997; 419: 112-6.
21. Evers R, Kool M, van Deemter L et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998; 101: 1310-9.
22. Schinkel AH, Wagenaar E, Mol CA et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-24.
23. Weiss J, Dormann SM, Martin-Facklam M et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204.
24. Boesch D, Gaveriaux C, Jachez B et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226-33.
25. Weiss J, Weis N, Ketabi-Kiyanvash N et al. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 2008; 579: 104-9.
26. Gupta A, Mugundu GM, Desai PB et al. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 2008; 36: 1172-80.
27. Weiss J, Herzog M, Konig S et al. Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 2009; 109: 242-50.
28. Frohlich M, Albermann N, Sauer A et al. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 2004; 68: 2409-16.
29. Weiss J, Haefeli WE. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos 2006; 34: 203-7.
30. Weiss J, Rose J, Storch CH et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007; 59: 238-45.
31. Chandler B, Almond L, Ford J et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003; 33: 551-6.
32. Peters T, Lindenmaier H, Haefeli WE et al. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 291-9.
33. Bierman WF, Scheffer GL, Schoonderwoerd A et al. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 2010; 65: 1672-80.
34. König SK, Herzog M, Theile D, et al. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010; 34: 2319-28.
35. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
36. Albermann N, Schmitz-Winnenthal FH, Z'Graggen K et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949-58.
37. Ding R, Tayrouz Y, Riedel KD et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004; 76: 73-84.
38. Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 2007; 28: 13-8.
39. Bakos E, Evers R, Sinko E et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000; 57: 760-8.
40. Zelcer N, Huisman MT, Reid G et al. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem 2003; 278: 23538-44.
41. Storch CH, Theile D, Lindenmaier H et al. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73: 1573-81.
42. Schurmann D, Fatkenheuer G, Reynes J et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21: 1293-9.
43. Fenner KS, Troutman MD, Kempshall S et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85: 173-81.
44. Brainard DM, Friedman EJ, Jin B et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 2010; doi:10.1177/0091270010367652.
45. Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009; 49: 377-94.
46. DeJesus E, Berger D, Markowitz M et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43: 1-5.
47. Kawabata S, Oka M, Soda H et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003; 9: 3052-7.
48. Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005; 39: 307-12.
49. Plasschaert SL, de Bont ES, Boezen M et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005; 11: 8661-8.
50. Wang H, Faucette S, Moore R et al. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 2004; 279: 29295-301.
51. Gutmann H, Fricker G, Torok M et al. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 1999; 16: 402-7.
52. Pascolo L, Fernetti C, Pirulli D et al. Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun 2003; 303: 259-65.
53. Alcorn J, Lu X, Moscow JA et al. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther 2002; 303: 487-96.
54. Szakacs G, Annereau JP, Lababidi S et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6: 129-37.
55. Sauerbrey A, Sell W, Steinbach D et al. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 2002; 118: 147-50.
56. Zisowsky J, Koegel S, Leyers S et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007; 73: 298-307.
57. Janneh O, Hartkoorn RC, Jones E et al. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 2008; 155: 875-83.
58. Cerveny L, Svecova L, Anzenbacherova E et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007; 35: 1032-41.
59. Yengi LG, Xiang Q, Pan J et al. Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem 2003; 316: 103-10.
60. Svecova L, Vrzal R, Burysek L et al. Azole antimycotics differentially affect rifampicin-induced pregnane X receptormediated CYP3A4 gene expression. Drug Metab Dispos 2008; 36: 339-48.
61. Weiss J, Sauer A, Divac N et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010; 31: 150-61.